Consensus Guidelines on the Testing and Clinical Management Issues Associated With HLA and Non-HLA Antibodies in TransplantationBrian D. Tait, Gerhard Opelz, Caner Süsal et al.|Transplantation|2012Cited by 777
Prognostic Impact of Early Treatment Interruption of Nivolumab Plus Ipilimumab Due to Immune-Related Adverse Events as First-Line Therapy for Metastatic Renal Cell Carcinoma: A Multi-Institution Retrospective StudyHiroki Ishihara, Kazunari Tanabe, Kazuhiko Yoshida et al.|Targeted Oncology|2021Cited by 9
Efficacy and Safety of Immunotherapy-Based Combinations as First-Line Therapy for Metastatic Renal Cell Carcinoma in Patients Who Do Not Meet Trial Eligibility CriteriaYuki Nemoto, Toshio Takagi, Hiroki Ishihara et al.|Targeted Oncology|2022Cited by 5